Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks

The compound [3-(1H-benzimidazol-2-methylene)-5-(2-methylphenylaminosulfo)-2-indolone], known as Indo5, is a novel selective inhibitor of c-Met and Trks, and it is a promising anticancer candidate against hepatocellular carcinoma (HCC). Assessing the pharmacokinetic properties, tissue distribution,...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Teng, Zhang, Fei-Xiang, Zhao, Ke, Gao, Hui-Ying, Zhang, Shou-Guo, Wang, Lin, Dou, Gui-Fang, Liu, Ting, Yu, Miao, Zhan, Yi-Qun, Chen, Hui, Yang, Xiao-Ming, Li, Chang-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383318/
https://www.ncbi.nlm.nih.gov/pubmed/34447310
http://dx.doi.org/10.3389/fphar.2021.711126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383318/
https://www.ncbi.nlm.nih.gov/pubmed/34447310
http://dx.doi.org/10.3389/fphar.2021.711126

Ejemplares similares